Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
12 hedge funds and large institutions have $5.97M invested in Aridis Pharmaceuticals Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
33% more capital invested
Capital invested by funds: $4.5M → $5.97M (+$1.47M)
9% more funds holding
Funds holding: 11 → 12 (+1)
1.76% more ownership
Funds ownership: 7.36% → 9.12% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$1.5M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$516K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$118K |
| 4 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$68.3K |
| 5 |
BlackRock
New York
|
+$18.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWM
Minot Wealth Management
Westwood,
Massachusetts
|
-$406K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3K |
ARDS Hedge Fund Activity: Q1 2021 in Review
12 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q1 2021, worth a combined $5.97M — up 33% from $4.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ARDS positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Roumell Asset Management, opening a new position worth an estimated $1.5M. The largest seller was Minot Wealth Management, cutting an estimated $406K.
- 12 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q1 2021, up from 11 in Q4 2020.
- Funds reported $5.97M of Aridis Pharmaceuticals Inc. Common Stock stock for Q1 2021, up 33% quarter-over-quarter.
- 4 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q1 2021 and 3 closed out, a net change of +1 holder.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q1 2021 was Roumell Asset Management, an estimated $1.5M added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q1 2021 was Minot Wealth Management, an estimated $406K sold.
Based on aggregated 13F filings for Q1 2021.